Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Andrea, Nadel"'
Autor:
Torsten Westermeier, Juergen Weber, Leonard Oppenheimer, Kenneth Todd Moore, Christopher C. Nessel, Andrea Nadel, Xiang Sun, Sanjay Jalota, Nancy Cook-Bruns, Gary Peters, Paul Burton, Guohua Pan, Frank Misselwitz, Elisabeth Perzborn, Peter M DiBattiste, Troy C. Sarich, Lloyd Haskell, Scott D. Berkowitz, Anthonie W. A. Lensing, Dagmar Kubitza
Publikováno v:
Annals of the New York Academy of Sciences. 1291:42-55
The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis-mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the p
Autor:
John M. Murkin, Bruce D. Spiess, Andrea Nadel, Simon C. Body, David Royston, Wulf Dietrich, Jerrold H. Levy, Jane C. K. Fitch
Publikováno v:
Anesthesia & Analgesia. 103:1082-1088
BACKGROUND: Inappropriate activation of hemostasis and inflammation may contribute to postoperative morbidity and mortality. The serine protease inhibitor, aprotinin, has been shown to prevent tissue and organ injury in laboratory and animal studies.
Autor:
Raymond C. Rosen, William A. Fisher, Joel Kaufman, Andrea Nadel, Ian Eardley, Michael Sand, Craig Niederberger
Publikováno v:
The Journal of Sexual Medicine. 1:150-160
Objective The aim of Phase II of the Men's Attitudes to Life Events and Sexuality (MALES) Study is to explore PDE5 inhibitor treatment seeking among men with erectile dysfunction (ED). Methods Phase II of the MALES study involved 2912 men, aged 20–
Autor:
Andrea Nadel, Ian Eardley, Michael Sand, William A. Fisher, Raymond C. Rosen, Craig Niederberger
Publikováno v:
Current Medical Research and Opinion. 20:607-617
The aims of the Men's Attitudes to Life Events and Sexuality (MALES) study were to identify prevalence of erectile dysfunction (ED) and related health issues in the general male population in Europe, North and South America, and to examine the attitu
Autor:
Andrea Nadel, Joseph Lipscomb, Lawrence H. Muhlbaier, Gregory P. Samsa, Santanu K. Datta, Peter K. Smith
Publikováno v:
The Annals of Thoracic Surgery. 77:635-642
Background The full kallikrein-inhibiting dose of aprotinin has been shown to reduce blood loss, transfusion requirements, and the systemic inflammatory response associated with cardiopulmonary bypass graft surgery (CABG). A half-dose regimen, althou
Publikováno v:
Circulation. 100:2353-2358
Background —Uncertainty exists regarding the frequency of early occlusion when the left internal mammary artery (LIMA) is anastomosed to the left anterior descending artery (LAD) through a sternotomy with conventional coronary artery bypass graftin
Autor:
Edwin L. Alderman, Bernardo A. Vidne, Moshe Nili, Charles B. Hantler, Gideon Uretzky, Bernard R. Chaitman, Jerrold H. Levy, Andrea Nadel, Hartzell V. Schaff, Jeffrey B. Rich, Jens J. Thiis, Gösta B. Pettersson
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 116(5):716-730
Objective: We examined the effects of aprotinin on graft patency, prevalence of myocardial infarction, and blood loss in patients undergoing primary coronary surgery with cardiopulmonary bypass. Methods: Patients from 13 international sites were rand
Autor:
Troy C, Sarich, Gary, Peters, Scott D, Berkowitz, Frank, Misselwitz, Christopher C, Nessel, Paul, Burton, Nancy, Cook-Bruns, Anthonie W A, Lensing, Lloyd, Haskell, Elisabeth, Perzborn, Dagmar, Kubitza, Kenneth T, Moore, Sanjay, Jalota, Juergen, Weber, Guohua, Pan, Xiang, Sun, Torsten, Westermeier, Andrea, Nadel, Leonard, Oppenheimer, Peter M, DiBattiste
Publikováno v:
Annals of the New York Academy of Sciences. 1291
The development of rivaroxaban (XARELTO®) is an important new medical advance in the field of oral anticoagulation. Thrombosis-mediated conditions constitute a major burden for patients, healthcare systems, and society. For more than 60 years, the p
Autor:
Jorge A. Marrero, Josep M. Llovet, Antonio Craxì, Armando Santoro, Guido Gerken, Michael Shan, Michel Beaugrand, M. Moscovici, Camillo Porta, Jean-Luc Raoul, Luigi Bolondi, Jordi Bruix, D. Voliotis, Morris Sherman, Vincenzo Mazzaferro, Angelo Sangiovanni, Peter R. Galle, Andrea Nadel
Publikováno v:
Journal of hepatology. 57(4)
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-prese
Autor:
Georgios Germanidis, Jean-Luc Raoul, Sergio Ricci, Max E. Scheulen, M. Moscovici, Vincenzo Mazzaferro, Sophie Dominguez, Andrea Nadel, Josep M. Llovet, Morris Sherman, D. Voliotis, Philip Hilgard, Hans Scherübl, Jordi Bruix, Tim F. Greten
Publikováno v:
Journal of hepatology. 56(5)
Background & Aims Hepatic markers are utilized in many classification systems of patients with hepatocellular carcinoma and, by measuring organ damage and tumor stage, can influence treatment. Moreover, elevated serum concentrations of aminotransfera